Jean Jacques Bienaime Sells 3,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $87.58, for a total transaction of $262,740.00. Following the completion of the transaction, the chief executive officer now directly owns 291,290 shares of the company’s stock, valued at approximately $25,511,178.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Thursday, January 10th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $90.55, for a total transaction of $271,650.00.
  • On Saturday, December 28th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.04, for a total transaction of $252,120.00.
  • On Friday, December 28th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.04, for a total transaction of $252,120.00.
  • On Wednesday, December 26th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $80.50, for a total transaction of $322,000.00.
  • On Friday, December 14th, Jean Jacques Bienaime sold 2,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $92.64, for a total transaction of $185,280.00.
  • On Wednesday, December 12th, Jean Jacques Bienaime sold 2,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $93.12, for a total transaction of $186,240.00.
  • On Thursday, November 1st, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $92.55, for a total transaction of $370,200.00.

NASDAQ:BMRN opened at $94.46 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $75.81 and a fifty-two week high of $106.74. The firm has a market cap of $16.18 billion, a P/E ratio of -140.99 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.26 and a current ratio of 2.87.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, October 25th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative return on equity of 2.98% and a negative net margin of 8.35%. The company had revenue of $391.71 million for the quarter, compared to the consensus estimate of $369.43 million. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post -0.13 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. Capital International Investors acquired a new stake in BioMarin Pharmaceutical during the third quarter worth about $204,025,000. Senator Investment Group LP purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at $94,200,000. Capital World Investors raised its holdings in shares of BioMarin Pharmaceutical by 34.3% in the 3rd quarter. Capital World Investors now owns 2,461,841 shares of the biotechnology company’s stock valued at $238,725,000 after buying an additional 628,738 shares during the period. First Trust Advisors LP raised its holdings in shares of BioMarin Pharmaceutical by 74.4% in the 3rd quarter. First Trust Advisors LP now owns 1,227,500 shares of the biotechnology company’s stock valued at $119,031,000 after buying an additional 523,649 shares during the period. Finally, Marshall Wace North America L.P. grew its stake in BioMarin Pharmaceutical by 86.2% during the 3rd quarter. Marshall Wace North America L.P. now owns 555,209 shares of the biotechnology company’s stock worth $53,839,000 after purchasing an additional 257,073 shares in the last quarter.

A number of equities research analysts have weighed in on BMRN shares. BidaskClub raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Cantor Fitzgerald set a $126.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Sunday, October 7th. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Canaccord Genuity upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $116.00 and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. Finally, ValuEngine upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, October 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $113.38.

TRADEMARK VIOLATION NOTICE: This story was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://transcriptdaily.com/2019/01/12/jean-jacques-bienaime-sells-3000-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

See Also: The risks of owning bonds

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply